Zasocitinib is under clinical development by Takeda Pharmaceutical and currently in Phase I for Systemic Lupus Erythematosus.

Secukinumab is under clinical development by Novartis and currently in Phase II for Coronavirus Disease 2019 (COVID-19) Pneumonia.

Psoriasis is a chronic inflammatory disease of the immune system that develops when the body makes skin cells too quickly, causing skin cells to pile up and form visible patches or spots on the skin.